Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Journal of Clinical Oncology

Volumn 27, Issue 33, 2009, Pages 5587-5593

  Tam, Constantine S ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a   Lynn, Alice ^a   Pierce, Sherry ^a   Zhou, Lingsha ^a   Keating, Michael J ^a   Thomas, Deborah A ^a   Verstovsek, Srdan ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 17; CHROMOSOME ABERRATION; CHRONIC DISEASE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOFIBROSIS; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; VALIDATION STUDY; AGE; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; HOSPITALIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; MYELOID METAPLASIA; NONPARAMETRIC TEST; PREDICTION AND FORECASTING; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL; TIME;

AGE FACTORS; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PREDICTIVE VALUE OF TESTS; PRIMARY MYELOFIBROSIS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, ESSENTIAL; TIME FACTORS;

EID: 73949151305     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.8833     Document Type: Article

References (23)

1. Mesa RA, Verstovsek S, Cervantes F, et al: Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 31:737-740, 2007
2. Dupriez B, Morel P, Demory JL, et al: Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 88:1013-1018, 1996
3. Elliott MA, Verstovsek S, Dingli D, et al: Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 31:1503-1509, 2007
4. Kerbauy DM, Gooley TA, Sale GE, et al: Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 13:355-365, 2007
5. Rondelli D, Barosi G, Bacigalupo A, et al: Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediateor high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105:4115-4119, 2005
6. Cervantes F, Barosi G, Demory JL, et al: Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102:684-690, 1998
7. Cervantes F, Dupriez B, Pereira A, et al: A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113: 2895-2901, 2009
8. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005
9. Giles FJ, Cortes JE, Kantarjian HM, et al: Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am 18: 753-774, 2004
10. Tam CS, Nussenzveig RM, Popat U, et al: The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 112: 1628-1637, 2008
11. Sokal JE, Cox EB, Baccarani M, et al: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799, 1984
12. Hasford J, Pfirrmann M, Hehlmann R, et al: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850-858, 1998
13. Kantarjian HM, Talpaz M: Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 6:180-182, 1988
14. Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
15. Tam CS, Abruzzo LV, Lin KI, et al: The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 113:4171-4178, 2009
16. Nussenzveig RH, Swierczek SI, Jelinek J, et al: Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35:32-38, 2007
17. Tefferi A, Mesa RA, Schroeder G, et al: Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 113:763-771, 2001
18. Huang J, Li CY, Mesa RA, et al: Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112:2726-2732, 2008
19. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
20. Königsberg R, Zojer N, Ackermann J, et al: Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 18:804-812, 2000
21. Cabanillas F, Pathak S, Grant G, et al: Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med 87:167-172, 1989
22. Grever MR, Lucas DM, Dewald GW, et al: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25: 799-804, 2007
23. Kantarjian HM, Dixon D, Keating MJ, et al: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441-1446, 1988